Publications by authors named "Jeanie F Woodruff"
Background: The validation of the Treatment-induced Neuropathy Assessment Scale (TNAS v2.0), a patient-reported outcome measure of symptoms associated with cancer treatment-induced peripheral neuropathy (TIPN), was previously reported. Further patient input (qualitative interviewing, cognitive debriefing) suggested that the measure should be modified to better reflect the TIPN experience.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of cancer treatment on peripheral neuropathy, focusing on a new assessment tool called the Treatment-Induced Neuropathy Assessment Scale (TNAS).
- The TNAS was evaluated for reliability and sensitivity through data from 573 patients, highlighting that numbness and tingling were the most severe symptoms, regardless of the type of cancer treatment.
- Findings suggest that nonpainful symptoms of neuropathy may be more disabling than painful ones, indicating a need for improved tools to measure these effects in clinical settings.
Fatigue is a distressing and persistent symptom for patients with gynecological cancer and for survivors. Debilitating cancer-related fatigue (CRF) is produced by both the disease and its treatment. Although awareness and study of CRF have grown in recent years, consistent assessment has not been a priority in routine medical practice.
View Article and Find Full Text PDFThe multiple symptoms arising from cancer and its treatment impose significant distress for patients. However, in clinical research, there is no agreed-upon way of assessing and presenting the effects of treatment on multiple symptoms, as either individual scores or a composite score. The ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force was established to make recommendations about measuring multiple symptoms as outcomes in cancer clinical trials.
View Article and Find Full Text PDFAlthough evidence of inflammation and fatigue has been noted in cancer survivors, whether inflammation is linked to the expression of fatigue and other symptoms arising from concurrent chemoradiation therapy (CXRT) has not been well studied. Patients undergoing CXRT for locally advanced colorectal or esophageal cancer (n=103) reported multiple symptoms weekly via the M. D.
View Article and Find Full Text PDFPurpose: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non-small-cell lung cancer and in patients treated at a tertiary cancer center.
Patients And Methods: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n=101) and three public hospitals treating the medically underserved (n=80).